Regeneron: Positive Initial Results From Covid-19 Treatment Published in NEJM
December 17 2020 - 5:07PM
Dow Jones News
By Stephen Nakrosis
Regeneron Pharmaceuticals Inc. said Thursday data from a
clinical trial of its antibody cocktail casirivimab and imdevimab
in non-hospitalized patients with Covid-19, published in the New
England Journal of Medicine, showed the treatment "effectively
reduced viral load and the need for medically-attended visits."
The data came from an ongoing seamless Phase 1/2/3 trial of the
treatment, the company said.
David Weinreich, SVP and Head of Global Clinical Development at
Regeneron and lead author of the publication, said "The
peer-reviewed NEJM publication of our first set of clinical data in
recently infected Covid-19 patients showed that casirivimab and
imdevimab effectively reduced viral load and the need for
medically-attended visits, with the greatest benefit in patients
who had not yet mounted their own effective immune response or had
high viral load at baseline."
George D. Yancopoulos, the company's President and Chief
Scientific Officer, said "These follow-on data provided the first
definitive prospective evidence demonstrating anti-viral activity
for a treatment regimen now available for Covid-19, and also
further documented the ability of this treatment to decrease the
need for further medical attention."
He also said "We are continuing to evaluate our antibody
cocktail in this outpatient setting, as well as in late-stage
trials in hospitalized patients and for prevention of infection,
and will continue to share our findings as quickly as
possible."
The company said it previously announced the initial results
featured in the publication from the Phase 1/2 portion of the trial
that enrolled 275 patients.
-Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 17, 2020 17:52 ET (22:52 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024